Chemotherapy Combined With Tislelizumab as Bladder Sparing Option for Patients With Muscle Invasive Bladder Cancer
Clinical trial NCT04909775 · UNKNOWN
Trial details
- NCT number
- NCT04909775
- Sponsor
- Ruijin Hospital
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2021-07-01
- Primary completion
- 2023-07-01
- Enrollment
- 40
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.